MedTrace Logo

The 5-FU Holter Study

NCT06538610 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-12-09

No results posted yet for this study

Summary

To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy

Conditions

  • Gastrointestinal Malignancy

Interventions

DEVICE

Holter monitor

Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3). Holter monitor to be worn for approximately 46-48 hours.

Sponsors & Collaborators

  • Gut Cancer Foundation

    collaborator UNKNOWN

  • Auckland City Hospital

    collaborator OTHER_GOV

  • The Heart Group

    collaborator UNKNOWN

  • University of Auckland, New Zealand

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-07-31
Completion
2026-01-31

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06538610 on ClinicalTrials.gov